Back

HCMV control in allogeneic stem cell transplant recipients - an analysis of humoral and cellular players beyond antigen-specific T cells in the letermovir era

2025-04-16 hematology Title + abstract only
View on medRxiv
Show abstract

Allogeneic hematopoietic stem cell transplant (alloSCT) recipients often experience late-onset human cytomegalovirus (HCMV) reactivations following termination of letermovir prophylaxis. Letermovir prophylaxis extends the window for protective B- and T-cell reconstitution; however, our understanding of humoral responses and their contribution to HCMV immune control remains limited. Combining serological and flow cytometric analyses in 42 HCMV-seropositive alloSCT recipients, we herein provide t...

Predicted journal destinations